We compared results obtained with a commercial immunoradiometnc assay kit for human thyrotropin in which monoclonal antibodies are used (Tandem-R TSH (ONE STEP) ImmunoRadioMetricAssay; Hybntech Inc.) with those obtained with two commercial radioimmunoassay methods: GAMMA-DAB#{174} ['25l]HS-hTSH AlA (Clinical Assays) and Thyro-SHure#{174} TSH Diagnostic Kit (Nuclear Medical Laboratories). The correlation of all results obtained in the Hybritech assay with those of the two commercial RIA5 exceeded 95%. Mean values for 100 euthyroid samples measured in the Hybritech assay were lower than for the other two methods. The separation between hyperthyroid and euthyroid patients was much clearer with the Hybritech assay than with the AlA methods. The Hybntech assay was far more sensitive than the Clinical Assays or the Nuclear Medical Laboratories assay.
(TSH)concentrations in serum in hyperthyroidismare extremely low (1) and have remained beyond the reach of commercial assay technology until very recently (2) . It is becoming increasingly apparent, however, that among the indices of thyroid status, such as total serum T4 and T3 concentrations, the value for serum TSH provides the most reliable index to the true physiological state of the patient (1).' For example, acute or chronic illness can lower T4 and T3 well into the hypothyroid range (3), leading, in the absence of TSH measurement, to a risk of inappropriate thyroid hormone replacement therapy. The continuing advances being made in TSH assay sensitivity now enable this single procedure to identify both extremes of thyroid dysfunction, leading to a valuable streamlining of the diagnostic process. We report here the comparison of a new one-step monoclonal immunoradiometric assay for TSH with two other commercial nonequilibrium radiolinmunoassay kit methods. We particularly examined the usefulness of each assay in discriminating euthyroid from hyperthyroid values for TSH. two-site immunoradiometric method involving two monoclonal antibodies directed against two different antigenic sites on the human TSH molecule. The beta-subunit-specific antibody is immobilized on a polystyrene bead. The alphasubunit-specific-antibody, which is radiolabeled with 'I, is supplied as a solution (composition not disclosed by the manufacturer).
Materials and Methods
The assay procedure is as follows. Place a single antibodycoatedbeadintoeachl2 x 75mmplastictesttube.
Add, in duplicate, 200 pL of calibrators (2 to 100 milli-int. units/L, plus zero calibrator) controls, and serum samples. Add 100 L of lrsIlabeled anti-TSH antibody (30000 cpm) to each tube, cover the rack, mix the contents of assay tubes by shaking, and incubate the tubes for 2 hat room temperature on a platform rotator set at 170 ± 10 rpm. Wash the beads twice by pipetting 2-mL portions of wash solution into each tube and aspirating the liquid from each tube. Count the radioactivity in each tube in a gamma counter and record the counts per minute. Construct a calibration curve by plotting, on a linear graph paper, the counts/mm bound for each calibrator vs the concentration of the corresponding calibrator, then fitting all the points by nonlinear least squares.
Second-order polynomial regression of dose vs counts/mm, derived by use of the Hewlett-Packard Model 9830 computer and the Hewlett-Packard polynomial regression program, gave an excellent least squares fit in most cases. When high accuracy near zero dose was needed, second-order polynomial least squares fitting of only the low-dose range of the standard curve was found to be equivalent to the cubic spine method used by the program incorporated into the GBmmR-Photon System, the gamma counter available from Hybritech.
Determine the concentration of TSH in the serum by interpolation from the curve.
For comparison, we correlated the Hybritech assay results with those of two other commercial radioixnmunoassays (RIAs). In the Clinical Assays GAMMA-DAB#{174} method for TSH measurement the conventional non-equilibrium double-antibody RIA procedure is used (2) .
We obtained the Thyro-SHure#{174} TSH Diagnostic Kit from Nuclear Medical Laboratories, Irving, TX (NML kit). 
Results
Hormone cross reactivities, defined as the measured TSH values in micrograms per liter divided by the concentration (in micrograms per liter) of the cross-reacting analyte added, in percent, were: for human choriogonadotropin, 7.0 x 10%; for lutropin (luteinizing hormone), 2.5 x 10%;
and for follitropin (follicle-stimulating hormone) 7.2 X 10-%.
Regression analysis for TSH concentrations as measured
with the Hybritech (y) and Clinical Assays (x) methods gave The Hybritech values for TSH in the euthyroid and hyperthyroid groups were significantly lower than those measured by the Clinical Assays and NML kits ( Table 1) .
Tests of 97 sera from hyperthyroid patients showed that TSH was undetectable in 25 samples (<0.1 milli-unitiL) in the Hybritechassay,in 29 samples (<1 milli-unitlL) by the Clinical Assays, and in 17 samples (<1 milli-unitlL) by the NML assay. Within-and between-assay CVs for the three methods are summarized in Table 2 . Figure 1 depicts representative standard curves for the three methods. The left-hand panel illustrates the nearly linear plot of bound counts vs the TSH dose for the Hybritech standard curve. The Clinical Assays (center) and NML (right) standard curves illustrate the fundamental differences between the Hybritech and conventional RIA methodologies. Figure 2 shows the distribution of TSH values for the hyperthyroid group as measured in the three assays. Note the extensive overlap of the NML and Clinical Assays data for hyperthyroid samples with their corresponding euthyroidranges ( Table 1) .
DIscussion
In the Hybritech one-step immunoradiometric assay for human TSH several technical advances are exploited that make possible a substantial improvement in assay sensitiv- (a) A bead-immobilized beta-subunit-specific monoclonal antibody removes the TSH from the incubation mixture. Because the amount of this antibody is in great excess with respect to the amount of TSH, even in hypothyroid serum samples, the binding of TSH molecules is nearly quantitative. Given a sufficiently sensitive detection system, and a bead-washing system that can remove all extraneous glycoproteins, the theoretical minimum detectable dose for the ixnmunoradiometric assay method becomes one molecule of PSI! (4). That for the radioimmunoassay, on the other hand, depends on the experimental error at zero dose divided by the antibody affinity constant. This constant in the best research radioimmunoassays may be near the theoretical limit, but improvements in methods for reducing the nonspecific signal at zero dose in the immunoradiometric assay (b) The radiolabel is attached to a monoclonal antibody with alpha-subunit binding specificity. lsaIradiolabeled gamma-globulins are more resistant to radiolytic damage than is I-labeled TSH (6), permitting greater betweenassay reproducibility.
(c) The minimum detectable concentration of 0.1 milliunitlL in a 200-zL sample, is among the lowest for current rapid, same-day TSH kit assay procedures.
(d) The assay is extremely simple and highly reproducible. The very low minimum detectable dose makes possible a greatly improved discrimination of samples from euthyroid and hyperthyroid patients ( Table 1) . The possibility of a real overlap between the low end of the euthyroid TSH range and that for hyperthyroid samples has not been completely ruled out. However, the present trend towards ever-increasing TSH assay sensitivity and the reports of essentially complete separation of these groups by use of ultrasensitive research assays for TSH (7, 8) suggest that detection of the hyperthyroid state on the basis of a single commercial-kit TSH assay may soon be feasible.
